AI tool to identify heart risks from chest CT scans
AutoChamber: an FDA-Designated Breakthrough AI Add-on to Coronary Artery Calcium and Lung Cancer Screening CT Scans to Flag Patients at High Risk of Atrial Fibrillation, Stroke and Heart Failure
['FUNDING_SBIR_1'] · HEARTLUNG CORPORATION · NIH-10922647
This study is testing a new AI tool called AutoChamber that looks at chest CT scans to find early signs of heart problems, helping to spot patients who might be at risk for issues like atrial fibrillation or stroke, all without needing any special dyes.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HEARTLUNG CORPORATION (nih funded) |
| Locations | 1 site (TORRANCE, UNITED STATES) |
| Trial ID | NIH-10922647 on ClinicalTrials.gov |
What this research studies
This research develops an AI tool called AutoChamber that analyzes chest CT scans to detect signs of heart conditions, such as enlarged cardiac chambers and thickened heart walls, without the need for contrast agents. By screening existing scans used for other medical evaluations, the tool aims to identify patients at high risk for atrial fibrillation, stroke, and heart failure. This innovative approach leverages the vast number of CT scans already performed to improve early detection and prevention of serious cardiovascular issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone chest CT scans for various medical evaluations, particularly those at risk for cardiovascular diseases.
Not a fit: Patients who have not had a chest CT scan or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier identification and management of heart conditions, potentially saving lives and reducing healthcare costs.
How similar studies have performed: Other research has shown promise in using AI for medical imaging, indicating that this approach could be effective in improving cardiovascular risk assessment.
Where this research is happening
TORRANCE, UNITED STATES
- HEARTLUNG CORPORATION — TORRANCE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAGHAVI, MORTEZA — HEARTLUNG CORPORATION
- Study coordinator: NAGHAVI, MORTEZA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.